Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

PHASE3CompletedINTERVENTIONAL
Enrollment

559

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 23, 2021

Study Completion Date

May 23, 2021

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Docetaxel + Plinabulin (DP)

Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2

DRUG

Docetaxel (D)

Docetaxel 75 mg/m2 IV

Trial Locations (57)

2148

Blacktown Cancer Centre, Blacktown

2250

Gosford Hospital, Gosford

2640

Border Medical Oncology Research Unit, East Albury

3121

Epworth Hospital, Richmond

3199

Peninsula and South East Oncology, Melbourne

4101

Adult Mater Hospital, South Brisbane

6000

Perth Oncology/Mount Hospital, Perth

6008

St John of God Hospital, Subiaco, Subiaco

6150

Fiona Stanley Hospital, Murdoch

15212

Allegheny Health Network, Pittsburgh

27157

Wake Forest Baptist Health, Winston-Salem

30318

Peachtree Hematoloy-Oncology Consultants, PC, Atlanta

39401

Hattiesburg Clinic Hematology/Oncology, Hattiesburg

40202

University of Louisville-Brown Cancer Center, Louisville

43623

Toledo Cancer Center, Toledo

45267

University of Cincinnati, Cincinnati

48202

Henry Ford Hospital, Detroit

48334

Michigan Center of Medical Research, Farmington Hills

60077

Orchard Healthcare Research Inc., Skokie

61801

Carle Cancer Center, Urbana

Cookeville Regional Medical Center Cancer Center, Cookeville

65613

Central Care Cancer Center, Bolivar

80909

Memorial Health Care System, Colorado Springs

85224

Ironwood Cancer & Research Centers, Chandler

90603

Innovative Clinical Research Institute, Whittier

92801

Pacific Cancer Medical Center, Inc., Anaheim

100013

Jilin Province Cancer Hospital, Changchun

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

100142

Beijing Cancer Hospital, Beijing

100853

The PLA General Hospital, Beijing

110042

Liaoning Cancer Hospital & Institute, Shenyang

150040

Affiliated Cancer Hospital of Harbin Medical Unive, Harbin

200030

Shanghai Chest Hospital, Shanghai Jiaotong Univers, Shanghai

200240

The Fifth People's Hospital of Shanghai, Shanghai

210009

Jiangsu Cancer Hospital, Nanjing

214400

Jiangyin People's Hospital, Jiangyin

226361

Nantong Tumor Hospital, Nantong

230000

Anhui Provincial Hospital, Hefei

250117

Shandong Cancer Hospital, Jinan

264000

Yantai Yuhuangding Hospital, Yantai

276000

527-Linyi Cancer Hospital, Linyi

300060

Tianjin People's Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University, Hanzhou

310016

Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

330000

Jiangxi Provincial Tumor Hospital, Nanchang

361000

The First Affiliated Hospital of Xiamen University, Xiamen

Zhongshan Hospital Xiamen University, Xiamen

410011

The Second Xiangya Hospital of Central South Unive, Changsha

450008

Henan Cancer Hospital, Zhengzhou

550002

Guizhou Provincial Hospital, Guiyang

610041

West China Hospital of Sichuan University, Chengdu

710061

The First Affiliated Hospital of Xi'an Jiaotong U, Xi'an

830011

Affiliated Tumor Hospital of Xinjiang Medical Univ, Ürümqi

06062

Cancer Center of Central Connecticut, Plainville

00913

Kansas University Medical Center, Westwood

050011

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

BeyondSpring Pharmaceuticals Inc.

INDUSTRY